PL2001891T3 - Pochodne buprenorfiny i ich zastosowania - Google Patents

Pochodne buprenorfiny i ich zastosowania

Info

Publication number
PL2001891T3
PL2001891T3 PL07732177T PL07732177T PL2001891T3 PL 2001891 T3 PL2001891 T3 PL 2001891T3 PL 07732177 T PL07732177 T PL 07732177T PL 07732177 T PL07732177 T PL 07732177T PL 2001891 T3 PL2001891 T3 PL 2001891T3
Authority
PL
Poland
Prior art keywords
buprenorphine derivatives
buprenorphine
derivatives
Prior art date
Application number
PL07732177T
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
John William Lewis
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of PL2001891T3 publication Critical patent/PL2001891T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07732177T 2006-03-28 2007-03-27 Pochodne buprenorfiny i ich zastosowania PL2001891T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
EP07732177.6A EP2001891B1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PL2001891T3 true PL2001891T3 (pl) 2014-03-31

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07732177T PL2001891T3 (pl) 2006-03-28 2007-03-27 Pochodne buprenorfiny i ich zastosowania

Country Status (21)

Country Link
US (1) US7964610B2 (pl)
EP (1) EP2001891B1 (pl)
JP (1) JP5167446B2 (pl)
KR (1) KR101430626B1 (pl)
CN (2) CN101410402A (pl)
AU (1) AU2007231133B2 (pl)
BR (1) BRPI0709157A8 (pl)
CA (1) CA2647417C (pl)
DK (1) DK2001891T3 (pl)
ES (1) ES2432169T3 (pl)
GB (1) GB0606124D0 (pl)
IL (1) IL193917A (pl)
MX (1) MX2008011984A (pl)
MY (1) MY151025A (pl)
NZ (1) NZ570997A (pl)
PL (1) PL2001891T3 (pl)
PT (1) PT2001891E (pl)
RU (1) RU2435773C2 (pl)
TW (1) TWI501969B (pl)
WO (1) WO2007110636A1 (pl)
ZA (1) ZA200807614B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562177A3 (en) * 2006-09-22 2013-04-10 AllTranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
EP2307420B1 (en) * 2008-04-24 2011-11-30 Janssen Pharmaceutica NV Nalmefene di-ester prodrugs
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
CA3002082A1 (en) * 2015-10-26 2017-05-04 Orphomed, Inc. Ethylene glycol ether of buprenorphine
CA3016510A1 (en) 2016-03-09 2017-09-14 Indivior Uk Limited Abuse-resistant pharmaceutical formulations
HRP20230062T8 (hr) * 2016-09-13 2023-04-14 Alar Pharmaceuticals Inc. Formulacije buprenorfina sa produženim oslobađanjem
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
BR112020016576A2 (pt) * 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
JP2003522146A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． 外圧に抵抗性の経口オピオイドアゴニスト製剤
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
AU2002337686B2 (en) 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1596824A4 (en) 2003-02-04 2011-11-23 Chrysalis Tech Inc AEROSOL FORMULATIONS AND AEROSOL DISTRIBUTION OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
RU2435773C2 (ru) 2011-12-10
JP5167446B2 (ja) 2013-03-21
CN104151320A (zh) 2014-11-19
BRPI0709157A2 (pt) 2011-06-28
JP2009531406A (ja) 2009-09-03
ES2432169T3 (es) 2013-12-02
WO2007110636A1 (en) 2007-10-04
MX2008011984A (es) 2008-10-03
AU2007231133B2 (en) 2011-09-01
CN101410402A (zh) 2009-04-15
DK2001891T3 (da) 2013-11-04
CA2647417C (en) 2014-09-23
AU2007231133A8 (en) 2011-08-25
NZ570997A (en) 2011-08-26
AU2007231133A1 (en) 2007-10-04
KR101430626B1 (ko) 2014-08-18
AU2007231133A2 (en) 2008-10-16
EP2001891A1 (en) 2008-12-17
IL193917A (en) 2014-12-31
CA2647417A1 (en) 2007-10-04
BRPI0709157A8 (pt) 2018-04-24
PT2001891E (pt) 2013-10-30
US20100234412A1 (en) 2010-09-16
US7964610B2 (en) 2011-06-21
GB0606124D0 (en) 2006-05-03
TW200806672A (en) 2008-02-01
MY151025A (en) 2014-03-31
EP2001891B1 (en) 2013-07-24
RU2008142527A (ru) 2010-05-10
ZA200807614B (en) 2009-10-28
KR20080105124A (ko) 2008-12-03
TWI501969B (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
ZA200810323B (en) Fkbp-l and uses thereof
TWI561237B (en) Substituted dihydropyrazolones and their use
HK1117535A1 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
LT2064327T (lt) Dbait ir jų panaudojimas
ZA200807614B (en) Buprenorphine derivatives and uses thereof
HK1208000A1 (en) Thioninium compounds and their use
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
GB0621160D0 (en) Compounds and uses thereof
GB0611115D0 (en) Compounds and their use
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP2124908A4 (en) CONNECTIONS AND ITS USE
EP2120563A4 (en) CONNECTIONS AND ITS USES
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
GB0605295D0 (en) Amino and derivatives
IL195430A0 (en) Arylsulfonamidyl tetralin derivatives and uses thereof
EP2099459A4 (en) COMPOUNDS AND USES THEREOF
GB0619611D0 (en) Compounds and their use
GB0610059D0 (en) Uses and methods
EP2120957A4 (en) COMPOUNDS AND USES THEREOF
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof
GB2444960B (en) Combined pseudoscope and hyperscope
GB0621665D0 (en) Blogmail and podmail
GB0606794D0 (en) Methods and uses
GB0614091D0 (en) Compounds and their uses